# GSK Pays $110M Upfront in Deal Worth Up to $1.3B for Hutchmed Cancer Drug

GSK has agreed to pay Hutchmed $110 million upfront for a first-in-class oncology candidate. The deal could reach a total value of $1.295 billion, including milestone payments. The asset targets KRAS and EGFR pathways and is in early-stage development.

The agreement gives GSK global rights to the investigational therapy, which is designed to address certain cancers driven by mutations in the KRAS gene. Hutchmed, a biopharmaceutical company based in China and Hong Kong, will continue to lead development in the near term.

**Context for the life sciences:** KRAS mutations have long been considered a difficult target in oncology. Recent advances have produced approved drugs for specific KRAS variants, but resistance often emerges. Combining KRAS inhibition with EGFR targeting is a newer strategy that may help delay or overcome resistance. This deal reflects continued industry interest in novel approaches to KRAS-driven cancers, a major area of unmet medical need.

Source: [original report](https://www.fiercebiotech.com/biotech/gsk-pens-13b-hutchmed-deal-early-stage-kras-egfr-cancer-asset)